Introduction to Sodium Iodide I-131
Sodium Iodide I-131, often referred to as I-131, is a radioactive isotope of iodine that plays a crucial role in both diagnostic and therapeutic medical applications. It is particularly significant in the treatment and diagnosis of thyroid-related conditions.
Clinical Uses of Sodium Iodide I-131
Diagnostic Applications
Sodium Iodide I-131 is used in the performance of radioactive iodide (RAI) uptake tests to evaluate thyroid function. These tests help in assessing thyroid hormone production and in localizing metastases associated with thyroid malignancies. It is also employed in differentiating between various types of hypo- or hyperfunctioning thyroid tissues and in evaluating nodularity and ectopic thyroid tissue[4].
Therapeutic Applications
I-131 is indicated for the treatment of hyperthyroidism and certain types of thyroid cancer. It is absorbed by the thyroid gland via the sodium/iodide symporter and subsequently destroys thyroid tissue through beta and gamma emissions. This makes it an effective treatment for conditions like hyperthyroidism and thyroid carcinomas that take up iodine[1][5].
Clinical Trials and Recent Developments
Iobenguane I-131 (Azedra)
One notable therapeutic application of I-131 is in the form of iobenguane I-131 (Azedra), which is used for the treatment of pheochromocytoma and paraganglioma. Although Progenics Pharmaceuticals announced the discontinuation of Azedra production and promotion as of August 2023, it remains an important example of I-131's therapeutic potential. Iobenguane I-131 targets tumors of neural crest origin by accumulating in cells that express the norepinephrine transporter, leading to cell death and tumor necrosis[1][2].
Ongoing Research
While specific recent clinical trials on Sodium Iodide I-131 itself may be limited due to its established use, ongoing research in nuclear medicine continues to explore new applications and improvements in radiopharmaceuticals. Advances in medical imaging technologies, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), are expected to further enhance the role of I-131 in diagnostic and therapeutic practices[3].
Market Analysis
Global Market Size and Growth
The global Sodium Iodide I-131 market is experiencing significant growth. As of 2023, the market was valued at approximately $239 million and is anticipated to reach $571 million by 2030, with a Compound Annual Growth Rate (CAGR) of 12.8% during the forecast period of 2024-2030[2].
Regional Market Segmentation
- Asia-Pacific: This region holds the largest market share, accounting for 36% of the global market. Countries like China, Japan, and India are driving this growth due to their expanding healthcare infrastructure and increasing demand for advanced diagnostic and therapeutic solutions[2].
- North America: This region accounts for 29% of the global market, with the United States and Canada being key players. The market here is driven by advanced healthcare facilities and a high demand for nuclear medicine applications[2].
- Europe: Europe holds a 27% share of the global market, with countries like Germany, France, and the UK contributing significantly to the growth[2].
Product Type and Application Segmentation
- Capsules: The capsule form of Sodium Iodide I-131 is the largest segment, accounting for 61% of the market. This is due to its ease of administration and precise dosing capabilities[2].
- Hyperthyroidism Treatment: This application dominates the market, with a share of 95%. The use of I-131 in treating hyperthyroidism and thyroid cancer is well-established and continues to drive market growth[2].
Market Projections
Future Growth Drivers
- Advancements in Medical Imaging: The growth of molecular imaging techniques, such as PET and SPECT, is expected to enhance the role of Sodium Iodide I-131 in diagnostic imaging and cancer treatment[3].
- Emerging Markets: The expansion of healthcare infrastructure in emerging markets, particularly in Asia-Pacific, Latin America, and Africa, will increase the demand for diagnostic and therapeutic solutions incorporating Sodium Iodide I-131[3].
- Government Support: Government investments in healthcare and nuclear medicine research, such as the U.S. government's allocation of $4.5 billion for nuclear medicine research in 2021, will indirectly benefit the Sodium Iodide I-131 market[3].
Market Size Projections
- The global Sodium Iodide I-131 market is projected to reach $571 million by 2030, up from $239 million in 2023[2].
- The global Iodine-131 market, specifically, is anticipated to grow from $1,859.21 thousand in 2023 to $2,578.25 thousand by 2030, with a CAGR of 5.06% during the forecast period[5].
Key Players and Competitive Landscape
The top players in the Sodium Iodide I-131 market include Curium Pharma, China Isotope & Radiation Corporation (CIRC), and Jubilant Pharmova. These companies hold over 75% of the market share and are driving innovation and supply in the sector[2].
Emerging Trends
Increased Use in Radiopharmaceuticals
The use of Sodium Iodide I-131 in radiopharmaceuticals is on the rise, driven by advancements in nuclear medicine and the growing demand for non-invasive diagnostic imaging techniques[3].
Partnerships and Collaborations
Partnerships between pharmaceutical companies and healthcare providers are expected to drive further market growth by creating more effective and less invasive treatments[3].
Safety and Contraindications
Contraindications
Sodium Iodide I-131 is contraindicated in women who are or may become pregnant due to the potential harm it can cause to the fetal thyroid gland. It is also important to rule out pregnancy in women of childbearing age before administering this drug[4].
Key Takeaways
- Established Use: Sodium Iodide I-131 is widely used in the diagnosis and treatment of thyroid-related conditions.
- Market Growth: The global market is projected to grow significantly, driven by advancements in medical imaging and increasing demand in emerging markets.
- Regional Dominance: Asia-Pacific, North America, and Europe are the leading regions in the Sodium Iodide I-131 market.
- Future Drivers: Government support, emerging market growth, and advancements in radiopharmaceuticals will drive future market expansion.
FAQs
What is Sodium Iodide I-131 used for?
Sodium Iodide I-131 is used for both diagnostic and therapeutic purposes, particularly in evaluating thyroid function and treating conditions like hyperthyroidism and certain types of thyroid cancer.
What are the key drivers of the Sodium Iodide I-131 market?
The key drivers include advancements in medical imaging technologies, growing demand in emerging markets, and government support for healthcare and nuclear medicine research.
Which regions dominate the Sodium Iodide I-131 market?
Asia-Pacific, North America, and Europe are the dominant regions in the Sodium Iodide I-131 market.
What are the contraindications for Sodium Iodide I-131?
Sodium Iodide I-131 is contraindicated in women who are or may become pregnant due to its potential harm to the fetal thyroid gland.
What is the projected market size of Sodium Iodide I-131 by 2030?
The global Sodium Iodide I-131 market is projected to reach $571 million by 2030.
Sources
- Carelon Clinical Guidelines: Therapeutic Radiopharmaceuticals 2025-03-23.
- QYResearch: Global Sodium Iodide I-131 Kits and Capsules Market Research Report 2024.
- Market.US: Sodium Iodide Market Size, Share | CAGR of 6.2%.
- DRAXIMAGE: DRAXIMAGE® I-131 Diagnostic Capsules.
- QYResearch: Global Iodine-131 Market Research Report 2024.
